Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV-DNA level < 2000 IU/mL.

Lee, Hankil; Jang, Sungin; Ahn, Sang Hoon; Kim, Beom Kyung

Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV-DNA level < 2000 IU/mL.

Lee, Hankil; Jang, Sungin; Ahn, Sang Hoon; Kim, Beom Kyung.

Affiliation

Lee H; College of Pharmacy, Ajou University, Suwon, Gyeonggi-do, Republic of Korea.
Jang S; Institute of Health Services Research, Yonsei University, Seoul, Republic of Korea.
Ahn SH; Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim BK; Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.

Hepatol Int ; 16(2): 294-305, 2022 Apr.

Article in En | MEDLINE | ID: mdl-35322374

Subject(s)

Carcinoma, Hepatocellular; Hepatitis B, Chronic; Liver Neoplasms; Antiviral Agents; Carcinoma, Hepatocellular/pathology; Cost-Benefit Analysis; DNA, Viral; Hepatitis B virus/genetics; Hepatitis B, Chronic/complications; Hepatitis B, Chronic/drug therapy; Hepatitis B, Chronic/pathology; Humans; Liver Cirrhosis/pathology; Liver Neoplasms/pathology; Middle Aged

Key words

Antiviral therapy; Compensated cirrhosis; Cost-effectiveness analysis; Hepatitis B virus; Low-level viremia

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Hepatitis B, Chronic / Liver Neoplasms Type of study: Health_economic_evaluation / Prognostic_studies Limits: Humans / Middle aged Language: En Journal: Hepatol Int Year: 2022 Type: Article

Fulltext

XML

PubMed Links

Search on Google